Blog
Published June 20, 2025
Reflecting on the first half of 2025 including data from AACR, ASCO and EHA, we see several notable trends continuing to shape the oncology landscape. While development follows momentum observed the last few years, these learnings provide a clearer understanding into the next wave of innovation.
Immunotherapy Moves Earlier in the Journey
One of the most notable themes is the continued momentum of PD-L1 therapies moving into earlier lines of treatment. New data supporting neoadjuvant use in solid tumors suggests…
Read Now
Blog
Published June 13, 2025
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to prepare for it.
What is the JCA?
The JCA is a centralized EU initiative designed to harmonize the clinical assessment component of Health Technology Assessments…
Read Now
Blog
Published June 9, 2025
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of ethics committee processes.
The MFG is a key part of Germany’s National Pharmaceutical Strategy, adopted by the federal cabinet in December 2023. This National…
Read Now
Webinars
Available On Demand
Join us for the first webinar in our “AI Innovations in Life Sciences” series to learn how generative AI (GenAI) can transform the way customer-facing teams (sales reps and medical science liaisons) operate in life sciences companies. Discover practical applications of GenAI to enhance call planning and customer engagement and help field teams translate data and analytics into action.Sales reps and MSLs face significant challenges in managing and synthesizing vast amounts of data from multiple sources. As companies prioritize the…
Watch Now
White Papers
Discover how Trinity Life Sciences is transforming pharma commercialization with generative AI (GenAI).
In this white paper, experts share how Trinity’s GenAI-powered solutions are reshaping Medical Affairs, Field Insights, Competitive Intelligence and more—delivering faster insights, reducing friction and unlocking new value across the organization.
What You’ll Learn:
How GenAI is being adopted across life sciences functions—and where it’s headed next
Real-world use cases in Medical Affairs, Field Insights, Value & Access, Primary Market Research and Competitive Intelligence
Trinity’s approach to…
Read Now
Case Studies
The Situation
Mid-Size Pharma, High-Potential HCP Identification
A mid-sized pharmaceutical company partnered with Trinity AI to revamp its targeting strategy with the goal of reinvigorating one of their brands across multiple indications to drive new patient growth.
They wanted to develop a robust autonomous dynamic targeting solution, leveraging AIML to identify microclusters of high potential HCPs to drive new patient starts.
The engine would predict and create a pipeline of HCPs that were most likely to convert to the brand…
Read Now
Blog
Published May 15, 2025
Data is the great enabler. It is the backbone of modern Customer Relationship Management (CRM) systems. Data enables businesses to understand their customers better, personalize interactions and make informed decisions. Companies that can harness the power of data have a competitive advantage now, but soon it will become a competitive disadvantage if they are unable to use this data.
“All too often we find that our clients struggle to access and organize their many sources of data into a comprehensive…
Read Now
Blog
Published May 8, 2025
The transformative potential of generative AI (GenAI) within the life sciences industry is highlighted in Everest Group’s report, “AI-deas to Action: Operationalizing Generative AI in Life Sciences.”
Fifteen companies were selected for inclusion across three categories:
Broad-based IT/Business Process Organizations (BPOs)
Clinical Research Organizations (CROs)
Life Sciences Specialists
To be included in the report, providers had to have been profiled in past Everest Group PEAK Matrix® assessments with a Harvey score of above five in Innovation and Investment, as…
Read Now
Blog
Published April 29, 2025
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While campaign rhetoric once suggested bold de-regulation with the potential for an industry-friendly reset, the governing reality has been less coherent and opens multiple fronts for…
Read Now
Webinars
Available On Demand
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies?
In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations. However, products with robust clinical differentiation or superiority can achieve price premiums over benchmarks.
Looking ahead, a recent policy to establish a Category C drug list is energizing the pharma industry, potentially providing coverage…
Watch Now
